Relationship of tumor prostaglandin levels to early recurrence in women with primary breast cancer: clinical update.
We have determined the levels of prostaglandin E (PGE) and PGF in 94 and 111 primary breast carcinoma specimens, respectively. Tumor specimens were obtained at the time of surgery for primary breast cancer from women without detectable metastatic disease (other than local lymph nodes). Prostaglandins were solvent extracted from tissue homogenates, separated into class by silicic acid chromatography and PG levels determined by radioimmunoassay. These findings were compared to clinically established prognostic indicators. All samples analyzed contained measurable amounts of both PG with a high correlation between levels of PGE and PGF. No association was seen between PG levels and either degree of lymph node involvement, or estrogen receptor. With increasing tumor grade (less differentiation, more pleomorphic nuclei, numerous mitotic figures) higher levels of both PGs were seen, but this association was not statistically significant. These women have been observed for an average of 30 months postsurgery. During that period 20% of tumors have recurred. No significant association were seen between either prostaglandin and the development of recurrent disease or death due to breast cancer. In contrast to published findings, we saw lower than average levels of both E and F in tumors metastasizing to the bone.